| Package | tw.gov.mohw.nhi.pas |
| Type | CodeSystem |
| Id | Id |
| FHIR Version | R4 |
| Source | https://nhicore.nhi.gov.tw/pas/https://build.fhir.org/ig/TWNHIFHIR/pas/CodeSystem-nhi-apply-reason.html |
| Url | https://nhicore.nhi.gov.tw/pas/CodeSystem/nhi-apply-reason |
| Version | 1.0.5 |
| Status | active |
| Date | 2025-05-05 |
| Name | NHIApplyReason |
| Title | NHI-健保事前審查-給付適應症 |
| Experimental | False |
| Realm | tw |
| Authority | national |
| Description | 臺灣衛生福利部中央健康保險署「給付適應症」代碼，代碼出版日期：2025-05-05；資料所屬單位：臺灣衛生福利部中央健康保險署。 |
| Content | complete |
| ValueSet | |
nhi-apply-reason  | NHI-健保事前審查-給付適應症值集 |
No resources found
Note: links and images are rebased to the (stated) source
Generated Narrative: CodeSystem nhi-apply-reason
This case-sensitive code system https://nhicore.nhi.gov.tw/pas/CodeSystem/nhi-apply-reason defines the following codes:
FHIR{
"resourceType" : "CodeSystem",
"id" : "nhi-apply-reason",
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p class=\"res-header-id\"><b>Generated Narrative: CodeSystem nhi-apply-reason</b></p><a name=\"nhi-apply-reason\"> </a><a name=\"hcnhi-apply-reason\"> </a><a name=\"nhi-apply-reason-en-US\"> </a><p>This case-sensitive code system <code>https://nhicore.nhi.gov.tw/pas/CodeSystem/nhi-apply-reason</code> defines the following codes:</p><table class=\"codes\"><tr><td style=\"white-space:nowrap\"><b>Code</b></td><td><b>Display</b></td><td><b>Definition</b></td></tr><tr><td style=\"white-space:nowrap\">C50P1<a name=\"nhi-apply-reason-C50P1\"> </a></td><td>早期乳癌-未發生腋下淋巴結轉移</td><td>事前審查品項代碼為KC010892B5、KC011162B5、JC00154261、KC009612B5(自113年12月擴增)、KC011112DE(114年1月起擴增)才可填寫</td></tr><tr><td style=\"white-space:nowrap\">C50P2<a name=\"nhi-apply-reason-C50P2\"> </a></td><td>早期乳癌-具腋下淋巴結轉移</td><td>事前審查品項代碼為KC009612B5、KC010892B5、KC011112DE、KC011162B5、KC011362B5、JC00154261才可填寫</td></tr><tr><td style=\"white-space:nowrap\">C50R1<a name=\"nhi-apply-reason-C50R1\"> </a></td><td>轉移性乳癌</td><td>事前審查品項代碼為KC009612B5、KC010892B5、KC011112DE、KC011162B5、KC011362B5、JC00154261才可填寫</td></tr><tr><td style=\"white-space:nowrap\">C16R1<a name=\"nhi-apply-reason-C16R1\"> </a></td><td>轉移性胃癌</td><td>事前審查品項代碼為KC009612B5、KC010892B5、KC011112DE、KC011162B5、KC011362B5、JC00154261才可填寫</td></tr><tr><td style=\"white-space:nowrap\">P001<a name=\"nhi-apply-reason-P001\"> </a></td><td>黑色素瘤</td><td>事前審查品項代碼為KC01013229、KC01013230、KC01025219才可填寫</td></tr><tr><td style=\"white-space:nowrap\">P011<a name=\"nhi-apply-reason-P011\"> </a></td><td>非小細胞肺癌-SQ-2線</td><td>事前審查品項代碼為KC01050238、KC01013229、KC01013230、KC01025219才可填寫</td></tr><tr><td style=\"white-space:nowrap\">P012<a name=\"nhi-apply-reason-P012\"> </a></td><td>非小細胞肺癌-Adeno-3線</td><td>事前審查品項代碼為KC01050238、KC01013229、KC01013230、KC01025219才可填寫</td></tr><tr><td style=\"white-space:nowrap\">P013<a name=\"nhi-apply-reason-P013\"> </a></td><td>非小細胞肺癌-1線</td><td>單用或併用，114年6月起擴增。事前審查品項代碼為KC01050238、KC01025219才可填寫(114年1月起擴增)</td></tr><tr><td style=\"white-space:nowrap\">P014<a name=\"nhi-apply-reason-P014\"> </a></td><td>鱗狀非小細胞肺癌第一線用藥(併用化療)</td><td>事前審查品項代碼為KC01025219才可填寫</td></tr><tr><td style=\"white-space:nowrap\">P021<a name=\"nhi-apply-reason-P021\"> </a></td><td>小細胞肺癌(併用化療)</td><td>事前審查品項代碼為KC01050238、KC01088229才可填寫</td></tr><tr><td style=\"white-space:nowrap\">P031<a name=\"nhi-apply-reason-P031\"> </a></td><td>典型何杰金氏淋巴瘤</td><td>事前審查品項代碼為KC01013229、KC01013230、KC01025219才可填寫</td></tr><tr><td style=\"white-space:nowrap\">P041<a name=\"nhi-apply-reason-P041\"> </a></td><td>泌尿道上皮癌-2線</td><td>事前審查品項代碼為KC01013229、KC01013230、KC01025219、KC01050238(113/8/1停止新病人給付)才可填寫</td></tr><tr><td style=\"white-space:nowrap\">P042<a name=\"nhi-apply-reason-P042\"> </a></td><td>泌尿道上皮癌-1線</td><td>事前審查品項代碼為KC01025219、KC01050238(113/8/1停止新病人給付)才可填寫</td></tr><tr><td style=\"white-space:nowrap\">P043<a name=\"nhi-apply-reason-P043\"> </a></td><td>局部晚期或轉移性泌尿道上皮癌之維持療法</td><td>事前審查品項代碼為KC01085229才可填寫</td></tr><tr><td style=\"white-space:nowrap\">P052<a name=\"nhi-apply-reason-P052\"> </a></td><td>胃癌-1線(併用化療)</td><td>事前審查品項代碼為KC01013230才可填寫</td></tr><tr><td style=\"white-space:nowrap\">P061<a name=\"nhi-apply-reason-P061\"> </a></td><td>腎細胞癌</td><td>事前審查品項代碼為KC01013229、KC01013230才可填寫</td></tr><tr><td style=\"white-space:nowrap\">P072<a name=\"nhi-apply-reason-P072\"> </a></td><td>晚期肝細胞癌-1線(併用標靶bevacizumab)</td><td>事前審查品項代碼為KC01050238、KC01088229才可填寫</td></tr><tr><td style=\"white-space:nowrap\">P081<a name=\"nhi-apply-reason-P081\"> </a></td><td>頭頸部鱗狀細胞癌第二線用藥</td><td>事前審查品項代碼為KC01013229、KC01013230、KC01025219才可填寫</td></tr><tr><td style=\"white-space:nowrap\">P082<a name=\"nhi-apply-reason-P082\"> </a></td><td>頭頸部鱗狀細胞癌第一線用藥</td><td>事前審查品項代碼為KC01025219才可填寫</td></tr><tr><td style=\"white-space:nowrap\">P091<a name=\"nhi-apply-reason-P091\"> </a></td><td>默克細胞癌</td><td>事前審查品項代碼為KC01085229才可填寫</td></tr><tr><td style=\"white-space:nowrap\">P101<a name=\"nhi-apply-reason-P101\"> </a></td><td>食道鱗狀細胞癌</td><td>事前審查品項代碼為KC01013230才可填寫</td></tr><tr><td style=\"white-space:nowrap\">P111<a name=\"nhi-apply-reason-P111\"> </a></td><td>惡性肋膜間皮瘤(ipilimumab併用nivolumab 120mg)</td><td>事前審查品項代碼「先申請KC00958229，再申請KC01013230」才可填寫</td></tr><tr><td style=\"white-space:nowrap\">P121<a name=\"nhi-apply-reason-P121\"> </a></td><td>膽道癌(併用化療)</td><td>事前審查品項代碼為KC01088229才可填寫</td></tr><tr><td style=\"white-space:nowrap\">P131<a name=\"nhi-apply-reason-P131\"> </a></td><td>早期三陰性乳癌(併用化療)</td><td>KC01025219(114年6月起擴增)</td></tr><tr><td style=\"white-space:nowrap\">P141<a name=\"nhi-apply-reason-P141\"> </a></td><td>大腸直腸癌</td><td>KC01025219(114年6月起擴增)</td></tr></table></div>"
},
"url" : "https://nhicore.nhi.gov.tw/pas/CodeSystem/nhi-apply-reason",
"version" : "1.0.5",
"name" : "NHIApplyReason",
"title" : "NHI-健保事前審查-給付適應症",
"status" : "active",
"experimental" : false,
"date" : "2025-05-05",
"publisher" : "衛生福利部中央健康保險署",
"contact" : [
{
"name" : "衛生福利部中央健康保險署",
"telecom" : [
{
"system" : "url",
"value" : "https://www.nhi.gov.tw"
}
]
}
],
"description" : "臺灣衛生福利部中央健康保險署「給付適應症」代碼，代碼出版日期：2025-05-05；資料所屬單位：臺灣衛生福利部中央健康保險署。",
"caseSensitive" : true,
"content" : "complete",
"count" : 25,
"concept" : [
{
"code" : "C50P1",
"display" : "早期乳癌-未發生腋下淋巴結轉移",
"definition" : "事前審查品項代碼為KC010892B5、KC011162B5、JC00154261、KC009612B5(自113年12月擴增)、KC011112DE(114年1月起擴增)才可填寫"
},
{
"code" : "C50P2",
"display" : "早期乳癌-具腋下淋巴結轉移",
"definition" : "事前審查品項代碼為KC009612B5、KC010892B5、KC011112DE、KC011162B5、KC011362B5、JC00154261才可填寫"
},
{
"code" : "C50R1",
"display" : "轉移性乳癌",
"definition" : "事前審查品項代碼為KC009612B5、KC010892B5、KC011112DE、KC011162B5、KC011362B5、JC00154261才可填寫"
},
{
"code" : "C16R1",
"display" : "轉移性胃癌",
"definition" : "事前審查品項代碼為KC009612B5、KC010892B5、KC011112DE、KC011162B5、KC011362B5、JC00154261才可填寫"
},
{
"code" : "P001",
"display" : "黑色素瘤",
"definition" : "事前審查品項代碼為KC01013229、KC01013230、KC01025219才可填寫"
},
{
"code" : "P011",
"display" : "非小細胞肺癌-SQ-2線",
"definition" : "事前審查品項代碼為KC01050238、KC01013229、KC01013230、KC01025219才可填寫"
},
{
"code" : "P012",
"display" : "非小細胞肺癌-Adeno-3線",
"definition" : "事前審查品項代碼為KC01050238、KC01013229、KC01013230、KC01025219才可填寫"
},
{
"code" : "P013",
"display" : "非小細胞肺癌-1線",
"definition" : "單用或併用，114年6月起擴增。事前審查品項代碼為KC01050238、KC01025219才可填寫(114年1月起擴增)"
},
{
"code" : "P014",
"display" : "鱗狀非小細胞肺癌第一線用藥(併用化療)",
"definition" : "事前審查品項代碼為KC01025219才可填寫"
},
{
"code" : "P021",
"display" : "小細胞肺癌(併用化療)",
"definition" : "事前審查品項代碼為KC01050238、KC01088229才可填寫"
},
{
"code" : "P031",
"display" : "典型何杰金氏淋巴瘤",
"definition" : "事前審查品項代碼為KC01013229、KC01013230、KC01025219才可填寫"
},
{
"code" : "P041",
"display" : "泌尿道上皮癌-2線",
"definition" : "事前審查品項代碼為KC01013229、KC01013230、KC01025219、KC01050238(113/8/1停止新病人給付)才可填寫"
},
{
"code" : "P042",
"display" : "泌尿道上皮癌-1線",
"definition" : "事前審查品項代碼為KC01025219、KC01050238(113/8/1停止新病人給付)才可填寫"
},
{
"code" : "P043",
"display" : "局部晚期或轉移性泌尿道上皮癌之維持療法",
"definition" : "事前審查品項代碼為KC01085229才可填寫"
},
{
"code" : "P052",
"display" : "胃癌-1線(併用化療)",
"definition" : "事前審查品項代碼為KC01013230才可填寫"
},
{
"code" : "P061",
"display" : "腎細胞癌",
"definition" : "事前審查品項代碼為KC01013229、KC01013230才可填寫"
},
{
"code" : "P072",
"display" : "晚期肝細胞癌-1線(併用標靶bevacizumab)",
"definition" : "事前審查品項代碼為KC01050238、KC01088229才可填寫"
},
{
"code" : "P081",
"display" : "頭頸部鱗狀細胞癌第二線用藥",
"definition" : "事前審查品項代碼為KC01013229、KC01013230、KC01025219才可填寫"
},
{
"code" : "P082",
"display" : "頭頸部鱗狀細胞癌第一線用藥",
"definition" : "事前審查品項代碼為KC01025219才可填寫"
},
{
"code" : "P091",
"display" : "默克細胞癌",
"definition" : "事前審查品項代碼為KC01085229才可填寫"
},
{
"code" : "P101",
"display" : "食道鱗狀細胞癌",
"definition" : "事前審查品項代碼為KC01013230才可填寫"
},
{
"code" : "P111",
"display" : "惡性肋膜間皮瘤(ipilimumab併用nivolumab 120mg)",
"definition" : "事前審查品項代碼「先申請KC00958229，再申請KC01013230」才可填寫"
},
{
"code" : "P121",
"display" : "膽道癌(併用化療)",
"definition" : "事前審查品項代碼為KC01088229才可填寫"
},
{
"code" : "P131",
"display" : "早期三陰性乳癌(併用化療)",
"definition" : "KC01025219(114年6月起擴增)"
},
{
"code" : "P141",
"display" : "大腸直腸癌",
"definition" : "KC01025219(114年6月起擴增)"
}
]
}
XIG built as of ??metadata-date??. Found ??metadata-resources?? resources in ??metadata-packages?? packages.